Pfizer Mum On Consumer Business Plans As Analysts Say Spin-off
This article was originally published in The Pink Sheet
Executive Summary
Pfizer continues to review options for its consumer business, though analysts say a spin-off makes most sense. During its fourth-quarter earnings call, firm reported the division's US sales slumped 9% but 12% growth in international markets buoyed the worldwide results.
You may also be interested in...
Pfizer Consumer Health True To Form Pending Move To JV With GSK
Pfizer consumer health sales up 4% to $3.6bn in 2018 as it prepares to move business into JV with GSK anticipated to close in the second half of 2019. Following 2% growth in 2017, a flat year in 2016 and a dip in 2015, Pfizer's view is confirmed of consumer health as a reliable revenue stream but not a strong growth driver.
Pfizer Consumer Health True To Form Pending Move To JV With GSK
Pfizer consumer health sales up 4% to $3.6bn in 2018 as it prepares to move business into JV with GSK anticipated to close in the second half of 2019. Following 2% growth in 2017, a flat year in 2016 and a dip in 2015, Pfizer's view is confirmed of consumer health as a reliable revenue stream but not a strong growth driver.
Private Label Nexium OTC Buoys Perrigo As Pricing Trims Rx Revenues
Perrigo's third-quarter launch of private label Nexium24HR was primary contributor of $13m in new product sales in North America.